Ruxolitinib Cream Plus Corticosteroids for Facial Non-Segmental Vitiligo in Real-World Practice

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter observational study enrolling about 300 participants with active, progressive facial non-segmental vitiligo. Participants will use topical 1.5% ruxolitinib cream twice daily for up to 24 weeks, in combination with a corticosteroid regimen chosen by routine clinical care. The primary goal is to see how many patients achieve 75% or greater improvement in facial patches by week 12, with safety monitoring throughout the 24 weeks. Efficacy at Week 12 will be analyzed using multiple imputation to account for missing data. The study reflects real-world clinical practice rather than a controlled trial setting, and uses historical data to frame the expected improvement.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 12 years at the time of signing informed consent.
* Clinical diagnosis of non-segmental vitiligo with facial involvement, and total body surface area (BSA) depigmentation ≤ 10%.
* Diagnosed with progressive/active vitiligo meeting at least one of the following: Vitiligo Disease Activity (VIDA) score ≥ 3.

Clinical signs including trichrome vitiligo, confetti-like depigmentation, or Koebner phenomenon.

The extent of lesions under Wood's lamp is larger than that visible to the naked eye.

* Agrees to have no pregnancy plans and uses effective contraception during the study and up to 4 weeks after the last dose.
* Voluntarily signs the informed consent form and agrees to regular follow-up visits.

Exclusion Criteria:

* Diagnosis of other clinical forms of vitiligo (e.g., segmental vitiligo).
* Clinically diagnosed with stable vitiligo.
* Co-existing skin depigmentation disorders affecting efficacy evaluation (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, chemical leukoderma, tinea versicolor).
* Leukoderma lesions with more than 1/3 white hair, or lesions accompanied by white hair where the investigator assesses the probability of benefit from participating is low based on clinical experience.
* Contraindications to systemic corticosteroid use.
* Known hypersensitivity or allergy to the study medications or excipients.
* Known end-stage renal disease (ESRD) or currently undergoing renal replacement therapy (e.g., dialysis).
* Concurrent participation in other clinical studies.
* Any other condition which, in the investigator's judgment, makes the patient unsuitable for the study

Where it's running

• Shenzhen Hospital of Southern Medical University
  Shenzhen, Guangdong, China Recruiting
• Dongying People's Hospital
  Dongying, Shandong, China Recruiting
• The Second Hospital of Lanzhou University
  Lanzhou, China Recruiting
• People's Hospital of Ningxia Hui Autonomous Region
  Ningxiang, China Recruiting
• Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
  Shanghai, China Recruiting
• The First Affiliated Hospital of Xi'an Jiaotong University
  Xi'an, China Recruiting

Study contacts

• Study coordinator: ShanShan Li
• Email: lishanshan@cms.net.cn
• Phone: +86 18201346463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib

  We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07913672

• crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo

  This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.

  Recruiting Phase 3 Cairo University · Cairo · NCT07904910

• EB06 vs placebo for adults with non-segmental vitiligo

  This study tests whether EB06 given by IV can safely and effectively help adults with moderate to severe non-segmental vitiligo compared with placebo.

  Recruiting Phase 2 Edesa Biotech Inc. · Edmonton, Alberta and 4 other locations · NCT07889492

• DMR-001 in CALR-mutant myeloproliferative neoplasms

  This study tests DMR-001 alone for CALR-mutant essential thrombocythemia or myelofibrosis, and in combination with ruxolitinib for CALR-mutant myelofibrosis.

  Recruiting at 3 sites Phase 1 Damora Therapeutics · Birmingham, Alabama and 35 other locations · NCT07849231

• Testing WJ01024 Alone and with Ruxolitinib for Myelofibrosis with Splenomegaly

  This early-phase study tests whether WJ01024, by itself or with ruxolitinib, is safe and tolerable and whether it shows signs of activity in adults with myelofibrosis and enlarged spleen.

  Recruiting Phase 1 Henan Cancer Hospital · Zhengzhou, Henan · NCT07802405

• Belumosudil vs. Ruxolitinib for hepatic cGVHD after HSCT

  This trial tests whether belumosudil or ruxolitinib works better for hepatic chronic GVHD after a stem cell transplant in people 12 and older.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07794514

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.